Mesenchymal stromal/stem cells from perinatal sources: biological facts, molecular biomarkers, and therapeutic promises

被引：0
作者：
Mohammed Z. Allouh [1 ]
Syed Faizan Ali Rizvi [2 ]
Ali Alamri [2 ]
Yusuf Jimoh [3 ]
Salma Aouda [2 ]
Zakaria H. Ouda [3 ]
Mohammad I. K. Hamad [2 ]
Mick Perez-Cruet [3 ]
G. Rasul Chaudhry [4 ]
机构：
[1] Department of Anatomy, College of Medicine and Health Sciences, United Arab Emirates University, P. O. Box: 15551, Al Ain
[2] OU-WB Institute for Stem Cell and Regenerative Medicine, Oakland University, Rochester, 48309, MI
[3] Department of Biological Sciences, Oakland University, Rochester, 48309, MI
[4] College of Medicine and Health Sciences, Khalifa University, Abu Dhabi
[5] Department of Neurosurgery, Corewell Health, Royal Oak, MI
来源：
Stem Cell Research & Therapy | / 16卷 / 1期
基金：
美国国家卫生研究院;
关键词：
Degenerative disease; Multipotent; Progenitor cells; Regenerative medicine; Stem cells;
D O I：
10.1186/s13287-025-04254-0
中图分类号：
学科分类号：
摘要：
The use of mesenchymal stem cells (MSCs) from perinatal tissue sources has gained attention due to their availability and lack of significant ethical or moral concerns. These cells have a higher proliferative capability than adult MSCs and less immunogenic or tumorigenesis risk than fetal and embryonic stem cells. Additionally, they do not require invasive isolation methods like fetal and adult MSCs. We reviewed the main biological and therapeutic aspects of perinatal MSCs in a three-part article. In the first part, we revised the main biological features and characteristics of MSCs and the advantages of perinatal MSCs over other types of SCs. In the second part, we provided a detailed molecular background for the main biomarkers that can be used to identify MSCs. In the final part, we appraised the therapeutic application of perinatal MSCs in four major degenerative disorders: degenerative disc disease, retinal degenerative diseases, ischemic heart disease, and neurodegenerative diseases. In conclusion, there is no single specific molecular marker to identify MSCs. We recommend using at least two positive markers of stemness (CD29, CD73, CD90, or CD105) and two negative markers (CD34, CD45, or CD14) to exclude the hematopoietic origin. Moreover, utilizing perinatal MSCs for managing degenerative diseases presents a promising therapeutic approach. This review emphasizes the significance of employing more specialized progenitor cells that originated from the perinatal MSCs. The review provides scientific evidence from the literature that applying these progenitor cells in therapeutic procedures provides a greater regenerative capacity than the original primitive MSCs. Finally, this review provides a valuable reference for researchers exploring perinatal MSCs and their therapeutic applications. © The Author(s) 2025.
引用
收藏
相关论文
共 160 条
[1]  
Brown C., McKee C., Bakshi S., Walker K., Hakman E., Halassy S., Et al., Mesenchymal stem cells: cell therapy and regeneration potential, J Tissue Eng Regen Med, 13, pp. 1738-1755, (2019)
[2]  
Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Et al., Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement, Cytotherapy, 8, pp. 315-317, (2006)
[3]  
Beeravolu N., Brougham J., Khan I., McKee C., Perez-Cruet M., Chaudhry G.R., Human umbilical cord derivatives regenerate intervertebral disc, J Tissue Eng Regen Med, 12, pp. e579-e591, (2018)
[4]  
Beeravolu N., McKee C., Alamri A., Mikhael S., Brown C., Perez-Cruet M., Et al., Isolation and characterization of mesenchymal stromal cells from human umbilical cord and fetal placenta, J Vis Exp JoVE, (2017)
[5]  
Espinoza N., Peterson M., How to depolarise the ethical debate over human embryonic stem cell research (and other ethical debates too!), J Med Ethics, 38, pp. 496-500, (2012)
[6]  
Volarevic V., Markovic B.S., Gazdic M., Volarevic A., Jovicic N., Arsenijevic N., Et al., Ethical and safety issues of stem Cell-Based therapy, Int J Med Sci, 15, pp. 36-45, (2018)
[7]  
Ma J., Wu J., Han L., Jiang X., Yan L., Hao J., Et al., Comparative analysis of mesenchymal stem cells derived from amniotic membrane, umbilical cord, and chorionic plate under serum-free condition, Stem Cell Res Ther, 10, (2019)
[8]  
Deuse T., Stubbendorff M., Tang-Quan K., Phillips N., Kay M.A., Eiermann T., Et al., Immunogenicity and Immunomodulatory properties of umbilical cord lining mesenchymal stem cells, Cell Transpl, 20, pp. 655-667, (2011)
[9]  
Teoh P.L., Mohd Akhir H., Abdul Ajak W., Hiew V.V., Human mesenchymal stromal cells derived from perinatal tissues: sources, characteristics and isolation methods, Malays J Med Sci MJMS, 30, pp. 55-68, (2023)
[10]  
Hass R., Kasper C., Bohm S., Jacobs R., Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC, Cell Commun Signal CCS, 9, (2011)
12345678910